416 related articles for article (PubMed ID: 35106939)
1. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
[TBL] [Abstract][Full Text] [Related]
2. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of global longitudinal strain combined with cardiac biomarkers on early detection of anthracycline-related cardiac dysfunction.
Allam H; Kamal M; Bendary M; Osama A; El Eleimy HA; Bendary A
J Echocardiogr; 2023 Dec; 21(4):165-172. PubMed ID: 37453981
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
8. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
9. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
10. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.
Jin CL; Shi XG; Wang TT; Li HW; Zhang DX; Sheng Z; Xiao J; Yu YQ
BMC Cardiovasc Disord; 2023 Sep; 23(1):465. PubMed ID: 37715125
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
12. Two-dimensional speckle tracking echocardiography, a powerful method for the evaluation of anthracyclines induced left ventricular insufficiency.
Chen W; Jiao Z; Li W; Han R
Medicine (Baltimore); 2022 Oct; 101(42):e31084. PubMed ID: 36281099
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
[No Abstract] [Full Text] [Related]
14. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
17. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
El-Sherbeny WS; Sabry NM; Sharbay RM
J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
[TBL] [Abstract][Full Text] [Related]
18. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
19. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy.
Katsurada K; Ichida M; Sakuragi M; Takehara M; Hozumi Y; Kario K
Springerplus; 2014; 3():620. PubMed ID: 25392790
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
